NYMOX PHARMACEUTICALS HAS A LONG HISTORY OF BROKEN PROMISES AND BAFFLING DELAYS THAT WILL LIKELY CONTINUE

February 6, 2020

RESEARCH SUMMARY

Nymox Pharmaceuticals has existed for 31 years, without bringing any product or drug to market.

NYMX has made many broken promises, delays, and a withdrawal regarding applying for marketing approval in the US and EU.

A competitor met the same primary endpoint that NYMX failed to meet.

Management salaries are excessive, with the CEO receiving over $9M per year at the current share price.

We believe NYMX will crash in 2020 on an equity raise and continued lack of regulatory progress.

Nymox Pharmaceuticals has existed for 31 years, without bringing any product or drug to market.

NYMX has made many broken promises, delays, and a withdrawal regarding applying for marketing approval in the US and EU.

A competitor met the same primary endpoint that NYMX failed to meet.

Management salaries are excessive, with the CEO receiving over $9M per year at the current share price.

We believe NYMX will crash in 2020 on an equity raise and continued lack of regulatory progress.

Read the full report on Seeking Alpha here.

LEGAL DISCLAIMER

As of the publication date of our reports, White Diamond Research, along with its clients, affiliates, and related entities, may have a short position in the securities discussed and stand to realize significant gains in the event that the price of the stock declines. Use White Diamond Research at your own risk. You should do your own research and due diligence before making any investment decision. No information contained in our reports should be interpreted as financial advice.